NFKB1 and cancer: The anti-malarial drug, Quinacrine, has also been reported to have anti-cancer activity, especially against cancers in which p53 is mutated, due to its ability to activate p53 signalling pathways and resume normal tumour suppression, as well as suppressing NF-κB and inhibiting topoisomerase activity [74, 75].